Insufficient evidence for an association between iatrogenic Alzheimer’s disease and cadaveric pituitary‐derived growth hormone

by Clinical Neuropsychologist Online | Monday, July 22, 2024 | Dementia

Abstract A Nature Medicine paper published in January 2024 describes eight cases of iatrogenic Alzheimer’s disease in individuals who received cadaveric pituitary-derived human growth hormone. The paper’s conclusions argue for the transmissibility of...

How do care partners overcome the challenges associated with falls of community-dwelling older people with dementia? A qualitative study

by Clinical Neuropsychologist Online | Sunday, July 21, 2024 | Dementia

Dementia, Volume 23, Issue 7, Page 1152-1171, October 2024. Background and ObjectivesPrevious studies have found that falls among community-dwelling older people with dementia negatively impact the health and well-being of their relative/friend care partners. Limited...

Multimerization of TREM2 is impaired by Alzheimer’s disease–associated variants

by Clinical Neuropsychologist Online | Saturday, July 20, 2024 | Dementia

Abstract INTRODUCTION The immune receptor triggering receptor expressed on myeloid cells 2 (TREM2) is among the strongest genetic risk factors for Alzheimer’s disease (AD) and is a therapeutic target. TREM2 multimers have been identified in crystallography and...

CSF glial biomarkers are associated with cognition in individuals at risk of Alzheimer’s disease

by Clinical Neuropsychologist Online | Saturday, July 20, 2024 | Dementia

Abstract INTRODUCTION We examined whether baseline glial markers soluble triggering receptor expressed on myeloid cell 2 (sTREM2), chitinase 3-like protein 1 (YKL-40), and glial fibrillary acidic protein (GFAP) in cerebrospinal fluid (CSF), and plasma GFAP are...

Advancements in APOE and dementia research: Highlights from the 2023 AAIC Advancements: APOE conference

by Clinical Neuropsychologist Online | Saturday, July 20, 2024 | Dementia

Abstract INTRODUCTION The apolipoprotein E gene (APOE) is an established central player in the pathogenesis of Alzheimer’s disease (AD), with distinct apoE isoforms exerting diverse effects. apoE influences not only amyloid-beta and tau pathologies but also...

Optimizing cutpoints for clinical interpretation of brain amyloid status using plasma p‐tau217 immunoassays

by Clinical Neuropsychologist Online | Friday, July 19, 2024 | Dementia

Abstract INTRODUCTION We aimed to evaluate clinical interpretation cutpoints for two plasma phosphorylated tau (p-tau)217 assays (ALZpath and Lumipulse) as predictors of amyloid status for implementation in clinical practice. METHODS Clinical performance of plasma...